meplazumab
Add to cart
meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.
[accordions]
[accordion title= “Biological Description“]
| Description | meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. |
| In vivo | Compared to control group, meplazumab treatment significantly improved the discharged (p=0.006) and case severity (p=0.021) in critical and severe patients.?The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5];?p=0.014, HR=0.37, 95%CI[0.155-0.833]).?The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group.?No adverse effect was found in meplazumab-treated patients.?Interpretation:Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia with a favorable safety profile. |
[/accordion]
[accordions]
[accordion title= “Chemical Properties“]
| Molecular Weight | N/A |
| CAS No. | T9931 |
[/accordion]
[accordions]
[accordion title= “References and Literature“]
[/accordion]
Related Products
HOW CAN WE HELP YOU? Our specialists are to help you find the best product for your application. We will be happy to help you find the right product for the job.
TALK TO A SPECIALIST
Contact our Customer Care, Sales & Scientific Assistance
EMAIL US
Consult and asked questions about our products & services
DOCUMENTATION
Documentation of Technical & Safety Data Sheet, Guides and more..
NEWSLETTER
We gladly support you by keeping you updated on our latest products and the developments around our services.
ATLANTIS BIOSCIENCE PTE LTD
362 Upper Paya Lebar Rd, #07-15,
Singapore 534963
WeChat ID: +65 8608 0974
© 2015-2023 Atlantis Bioscience Pte Ltd. All rights reserved. Co Reg No: 201539516N